| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > Risk Management |
|
Advice You - Risk Management
Every business carries an element of risk. Therefore, managing risks is crucial process in many organizations. Dependi According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ng on the business, steps can be taken to reduce the frequency and intensity of risk. Risk management is a process or ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in roup in an organization that takes management action to reduce risk. This activity involves the process of measuring a lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. nd developing strategies to manage the risk. The strategies employed include transferring the risk to another party, a here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe oiding the risk, reducing the negative effect of risk, and accepting some or all of the consequences of a particular r d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro sk. There are two kinds of risk management. Traditional risk management is focused on risks stemming from physical an ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc d legal causes like natural disasters, accidents, death or lawsuits. Financial risk management focuses on risks that c easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi n be managed by using traded financial instruments. Large corporations employ risk management teams while smaller corp nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically rations practice informal, if not formal, risk management techniques that are rolled into the responsibilities of oper and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ational managers. Risk managers recognize and review their organizations loss exposures including property, liability, ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi personnel and net income. This helps promote growth through profit, continuous operation and stable earnings. The fun ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a tion of risk management is to organize and carry out a plan to control or reduce the risks to which a firm is exposed. dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod This planning involves a five-step process. The first step is to identify potential risks. The method of identifying cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin isks may depend on the organizational culture, industry practice and compliance. Once risks have been identified, the tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ext step is to assess the potential severity of loss and probability of occurrence. The third step is to find a potent t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ial treatment for the problem. This may involve the transfer, avoidance, reduction or retention of a potential risk. ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ext is to implement the plan by choosing the right method of treatment. Prior to implementation, a review and evaluati y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products n of the plan is necessary. Initial risk management plans are never perfect. Practice, experience and actual results, . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de will necessitate changes in the plan. Therefore, the plan should make room for flexibility in decision making. Risk m elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip nagement is considered an art in management circles and experience and exposure to situations helps mastering this art tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Secret Steps To Earning Money Online Change in Four Steps: How to Make Effective Changes at Work
|